Mygenia ctDNA - Early Cancer Screening

What is Cancer?

Cancer is a type of genetic disease that is often caused by accumulated DNA mutation. It normaly takes a few years and even a decade of time to develop a malignant tumour from DNA mutation.

Increasing incidence & mortality of cancer

- Cancer becomes the top killer in both HK and

mainland China

Affecting every one of us

- Nearly everyone has heard of real cancer cases

within their social circles

Targeting younger generation

- Cancer in young Chinese patient accounts for

almost 1/4 of the world’s dealth

Lower chance of survival

- Almost half of the cancer patients dignosed too late and

making treatment less likely to succeed

A breakthrough in ctDNA technology

Currently, there is a growing trend in early cancer screening by DNA examination worldwide. With the advances in sequencing technology, scientists have stepped forwards and demonstrated that ctDNA technology is applicable in most cancer types at both early and advanced stages.

What is ctDNA? A non-invasive cancer biomarker

A tumour itself is the major source of tumour DNA and dying tumour cells could release small pieces of their DNA into the bloodstream. These pieces are referred to circulating tumour DNA (ctDNA). Owing to its high specificity to tumour, ctDNA is regarded as an effective yet non-invasive cancer biomarker.

Cure for Cancer, Closer than You Think

ctDNA technology, as a non-invasive method for cancer screening, presents a low-risk yet effective assessment complementing traditional biopsies. We believe ctDNA technology could help monitor your health progressively and protect you from cancer.

Early screening technology by Pangenia R&D team

Specialising in high-throughput sequencing, bioinformatics and big data analysis, Pangenia Lifesciences commits to the development of early cancer screening technology. MYGENIA® ctDNA - Early Cancer Screening aims to lower the incidence and mortality of cancer by achieving early diagnosis. With the high sensitivity and selectivity, our test could assess your risk of cancer before it is too late to cure.

Catch cancer way before normal body check-up

As we all know, PET-CT is used in regular body check and could detect the presence of tumour. Yet, ctDNA technology leaps forwards by detecting the alternation of DNA sequence. It allows us to take action before tumour development and increases the chance of survival.

ctDNA screening procedure

Test Specifications

Test Code

Methodology

Specimen Requirements

Turnaround Time

OCT

Next generation sequencing (NGS)

10 mL blood

6 weeks

Advantages of MYGENIA® ctDNA - Early Cancer screening

Target gene is sequenced by advanced NGS technology
Genomic sequence of 50 genes examined
Average read depth reaches 30000 reads/gene
High sensitivity - mutation with occurance as low as 0.03% could be detected
High specificity - specificity exceeds 90%

MYGENIA® ctDNA - Early Cancer Screening

Circulating tumour DNA (ctDNA) Genetic Test

A single test estimating your risk of common cancers

Healthy individuals at all ages

Frequent exposure to radioactive environment
Unhealthy lifestyle
Smoking, excessive drinking unbalanced diet
Overweight, lack of exercise
Individual with chronic disease or poor immunit
Concerns about getting malignant tumour Individuals with family history of cancer
Multiple family members with same cancer type
Two immediate family members or above with rare tumour disease

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

References

reference 1
reference 2
reference 3